Fig. 2From: Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center studyCorrelation between visual acuity and central subfield thickness for eyes with visual impairment from center-involved diabetic macular edema following intravitreal bevacizumab injections over a study period: a at baseline; b at 3Â months; and c at 12Â monthsBack to article page